Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anatole Besarab

Showing results (81-90 of 84) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 84 results.
Kidney International Reports|March 18, 2021
Roxadustat for CKD-related Anemia in Non-dialysis PatientsDaniel W Coyne, Simon D Roger, Sug Kyun Shin, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 21, 2016
Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKDRobert Provenzano, Anatole Besarab, Chao H Sun, et al.
Nephrology News & Issues|July 13, 2010
Which direction is right for vascular access surveillance? A debateKenneth Abreo, Michael Allon, Arif Asif, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 4, 2017
Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in ChinaNan Chen, Jiaqi Qian, Jianghua Chen, et al.
Pageof 9

Showing results (81-90 of 84) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 84 results.
Kidney International Reports|March 18, 2021
Roxadustat for CKD-related Anemia in Non-dialysis PatientsDaniel W Coyne, Simon D Roger, Sug Kyun Shin, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 21, 2016
Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKDRobert Provenzano, Anatole Besarab, Chao H Sun, et al.
Nephrology News & Issues|July 13, 2010
Which direction is right for vascular access surveillance? A debateKenneth Abreo, Michael Allon, Arif Asif, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 4, 2017
Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in ChinaNan Chen, Jiaqi Qian, Jianghua Chen, et al.
Pageof 9